

[For more information](#)




Optimizing Cell-Free System: From Basic Research to Industrial Applications

Reconstituted cell-free protein synthesis kit

PURE*frex*[®]

Takashi Ebihara, Ph.D.
COO
GeneFrontier Corporation




GeneFrontier

PEGS Boston
13-17 May 2024


PUREfres[®]

-Customize expression toolbox for your research-

Totally constructive, molecular based system





Only necessary molecules for transcription/translation



- ✓ Rebuilt cell-free system
- ✓ Tunable for your biologics
- ✓ Simple, Fast
- ✓ Suited for High throughput system
- ✓ Very low contaminants

For more information




Experimental conditions for protein synthesis

Reaction mixture	Incubation	Template DNA
PUREfres [®] 2.1 (4 mM GSH) + Surfactants	37°C 4 h	sfGFP PCR product (1 ng/μL)


Measurement of GFP fluorescence

- Most surfactants did not inhibit the protein synthesis reaction by PUREfres[®] below the CMC.
- Some surfactants such as Triton X-100 and Tween 20 could be used even above the CMC.




<Ex, Non-natural AA introduction>

Translation - RF1





<Ex, Membrane protein with Nanodisc; artificial membrane-like structure>



The condition of membrane protein synthesis

Reaction mix	Template DNA	Incubation
PUREfres [®] 2.0 +Nanodisc (MSP1E3D1-His POPC*, final 10 μM)	PCR product	37°C, 4 h


*Ref: Denisov et al. (2007) J.Biol.Chem., vol. 282, p. 7066.






-Improve Expression from Days to Hours-

PUREfres[®] Synthesis




Total: 2-4 hours

E. coli Expression




Total: 3-4 days



100mL package will be launched soon!






Great Flexibility from basic research to industrial applications






-Expression of scFv, Fab and more-




+/- DsbC Set
DnaK Mix
For correct folding

Activity



[Murakami et al. \(2019\) Sci. Rep. vol.9, p.671. \(Supplementary Information\)](#)



anti-CD3-scFv/CD19-scFv




	1	2	3	4	5	6	7	8	9	10
	Proinsulin Aspart	Proinsulin Lispro	Proinsulin Glargine	Regular Proinsulin	Insulin A Chain	Insulin B Chain	Insulin A Chain Heterodimer	Insulin B Chain Heterodimer	Oxytocin	Glucagon
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
CIm24	✗	✗	✗	✗	✓	✗	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✓	✗	✓	✓	✓	✗
759	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗
	11	12	13	14	15	16	17	18	19	20
	Glucagon Like Peptide 1 mutant (GLP-1 mut)	Glucagon Like Peptide 1 (GLP-1)	Insulin Like Growth Factor	Growth Hormone (GH)	Leptin	Vaso-pressin	Angiotensin II	Parathyroid Hormone (PTH)	Somato- statin	Leuprolide
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
CIm24	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✗	✗	✓	✓	✓	✓
759	✓	✓	✗	✓	✓	✓	✓	✗	✓	✓

[DeWinter et al. \(2023\) ACS Synth. Biol. vol.12, 4, p1216. \(Supplementary Information\)](#)

scFv-IL-2



CTLL-2 proliferation









-To harness the potential of translation-

Met-Glu-Val-Gln-Leu-Val-

Glu		Val		Gln		Leu		Val	
codon	Freq. (%)	codon	Freq. (%)	codon	Freq. (%)	codon	Freq. (%)	codon	Freq. (%)
gaa	70	ggt	25	caa	30	tta	15	ggt	25
gag	30	gtc	18	cag	70	ttg	12	gtc	18
		gta	17			ctt	12	gta	17
		gtg	40			ctc	10	gtg	40
						cta	5		
						ctg	46		



*Frequency is calculated from Codon Usage Database in Kazusa DNA Res. Inst. (E.coli K-12 strain)




C

	1	2	3	4	5	6	GC (%)	ΔG (kcal/mol)
Name	Met	Glu	Val	Gln	Leu	Val		
AT	atg	gaa	gta	caa	tta	ggt	28	0.0
Major	atg	gaa	gtg	cag	ctg	gtg	56	-4.7
GC	atg	gag	gtg	cag	ctg	gtc	61	-3.9


[Murakami et al. \(2024\) Int. J. Mol. Sci. 2024, 25\(10\), 5264](#)




-Broad applications, yet to come!-



[Fujita et al. \(2023\) ACS Nano. vol.17\(4\), p.3358.](#)




[Wong et al. \(2024\) bioRxiv <https://doi.org/10.1101/2024.03.25.586624>.](#)



[Tabuchi et al. \(2022\) Nucleic Acids Res <https://doi.org/10.1093/nar/gkac152>](#)


WET LAB EXPERIMENT: cell-free production and activity test of AMPs (24 hr)




[Pandi et al. \(2023\) Nat Communications. vol.14\(7197\).](#)



-Broad applications, yet to come!-




[Zimmermann I. et al. \(2018\) eLife, 7, e34317.](#)



[Tsuboyama et al. \(2023\) Nature, 620, p434.](#)

in vitro protein selection technology

PUREfres[®] RD




Licensed technology under JP4931135 etc.

◆ Advanced screening system for Biologics

- mAb (scFv / Fab)
- VHH
- Cyclic peptide

◆ High Selection Efficiency

- Completely molecular based system
- >10¹² diversity



Licensed to
SUTRO
BIOPHARMA

Contact information



Reconstituted cell-free protein synthesis kit

PUREfrex[®]

For reagent use for expression / screening of biologics

<https://purefrex.genefrontier.com/>



in vitro protein selection technology

PUREfrex[®]RD

*For screening service / collaboration / technology transfer
for generation of new biologics*

Takashi Ebihara, Ph.D., COO, GeneFrontier

[E-mail: ebihara@genefrontier.com](mailto:ebihara@genefrontier.com)